A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2014
An open label randomised trial for adults with histologically confirmed measurable metastatic GIST who have received no other treatment for metastatic disease. The study aims to determine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety in comparison to imatinib alone to warrant further evaluation as a first line treatment for metastatic GIST.
Epistemonikos ID: 0416804ad300bb3fe638dfe20b28be9d1f5111cf
First added on: Apr 12, 2022